NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, MBio Diagnostics said it is offering for sale $2.3 million of stock and warrant units.

The units consist of 10,000 shares of Series B-2 preferred stock and 10,000 warrants to purchase Series B-2 preferred stock. The company noted it has already raised $562,500, and plans to raise $1.7 million more.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.